Sotera Health sets Q2 2026 earnings release for August 6

1 min read     Updated on 23 Jul 2026, 05:50 PM
scanx
Reviewed by
Suketu GScanX News Team
AI Summary

Sotera Health Company announced the release of its Q2 2026 financial results for August 6, 2026, followed by a conference call at 9:00 a.m. ET. The company will provide a live webcast and replay via its Investor Relations website. Updates on investor matters and Ethylene Oxide are available online.

powered bylight_fuzz_icon
46354804

*this image is generated using AI for illustrative purposes only.

Sotera Health Company will release its financial results for the second quarter ended June 30, 2026, before the market opens on Thursday, August 6, 2026. The company, a global provider of sterilization solutions, lab testing, and advisory services, scheduled a conference call at 9:00 a.m. Eastern Daylight Time to discuss its operating and financial performance.

Conference Call Details

Management will review the quarterly results during the call, which will be accessible via a live webcast. Investors can access the webcast and accompanying materials through the Investor Relations section of the Sotera Health website. A replay of the webcast will be available later in the day on August 6.

Key Dates and Information

Event Date and Time
Q2 2026 Earnings Release August 6, 2026 (before market open)
Conference Call August 6, 2026 at 9:00 a.m. ET
Webcast Replay August 6, 2026 (later in the day)

Investor Resources

Updates on recent developments relevant to investors can be found on the Investor Relations section of the Sotera Health website. Specific updates related to Ethylene Oxide are also available on the company's site. Sotera Health operates through three businesses: Sterigenics®, Nordion®, and Nelson Labs®.

How will recent regulatory changes regarding Ethylene Oxide impact Sotera Health's operational costs and profitability in the coming quarters?

What growth strategies does management plan to implement to expand market share across its Sterigenics®, Nordion®, and Nelson Labs® businesses?

How might the company's financial performance be affected by potential shifts in demand for sterilization and lab testing services in the healthcare sector?

like20
dislike

Barclays raises Sotera Health price target to $19

0 min read     Updated on 24 Jun 2026, 09:29 PM
scanx
Reviewed by
Radhika SScanX News Team
AI Summary

Barclays analyst Luke Sergott maintained an Overweight rating on Sotera Health and raised the price target to $19 from $18.

powered bylight_fuzz_icon
43862351

*this image is generated using AI for illustrative purposes only.

Barclays analyst Luke Sergott has maintained an Overweight rating on Sotera Health (NASDAQ: SHC) and raised the price target to $19 from $18. The adjustment reflects a revised outlook on the company's stock performance.

Rating and Target Details

The brokerage's stance remains positive, as evidenced by the Overweight designation. The new price target represents an increase from the previous level of $18.

Metric Value
Rating Overweight
Previous Price Target $18
New Price Target $19

What specific factors drove Barclays to revise Sotera Health's price target upward?

How might Sotera Health's recent performance influence other analysts' ratings?

What are the potential risks that could prevent Sotera Health from reaching the new $19 target?

like18
dislike